Desensitization With Bortezomib Before a Living Kidney Donation
Status:
Unknown status
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
The investigators plan to study the role of bortezomib for desensitizing patients awaiting a
living kidney donation who have a titer of Donor Specific anti human leucocyte antigen (HLA)
Antibody (DSA) between 1000 and 3000 MFI with a pilot study of 10 patients recruited in 4
hospital in FRANCE.